Early on the morning of March 21, 2019, Nancy Childs awoke and, as is her habit, began scrolling through her news feed. There was bad news for her and her husband, Mike. Biogen and Eisai had abruptly halted their phase III trial of aducanumab to slow cognitive and functional impairment in persons with mild cognitive impairment (MCI) or dementia caused by Alzheimer disease. Headlines described the trial’s early end as “a major setback”1 and “a blow to hopes for new treatment.”2 Biogen’s stock plummeted with the news, posting its worst day in 14 years.3 The Childs’ hopes plummeted as well.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Largent EA, Karlawish J. Rescuing Research Participants After Alzheimer Trials Stop Early: Sending Out an SOS. JAMA Neurol. 2020;77(4):413–414. doi:10.1001/jamaneurol.2019.4974
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.